Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course

Leukemia Research

Volumn 36, Issue 7, 2012, Pages 826-831

  Bacher, Ulrike ^a   Kern, Wolfgang ^b   Alpermann, Tamara ^b   Schnittger, Susanne ^b   Haferlach, Claudia ^b   Haferlach, Torsten ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Classification; Cytogenetics; Cytomorphology; International Prognostic Scoring System (IPSS); Myelodysplastic syndromes (MDS); Ring sideroblasts

Indexed keywords

AZACITIDINE; CYTARABINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TRANSFUSION; CHROMOSOME ANALYSIS; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; SURVIVAL TIME; WATCHFUL WAITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; COHORT STUDIES; CYTOGENETICS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84862313893     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.003     Document Type: Article

References (23)

1. Brunning R., Bennett J., Matutes E., Orazi A., Vardiman J., Thiele J. Refractory cytopenia with multilineage dysplasia. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 98-99. IARC Press, Lyon. 4th ed. S. Swerdlow, E. Campo, N. Lee Harris, E. Jaffe, S. Pileri, H. Stein, J. Thiele, J. Vardiman (Eds.).
2. Hasserjian R., Gattermann N., Bennett J., Brunning R., Thiele J. Refractory anaemia with ring sideroblasts. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 96-97. IARC Press, Lyon. 4th ed. S. Swerdlow, E. Campo, N. Lee Harris, E. Jaffe, S. Pileri, H. Stein, J. Thiele, J. Vardiman (Eds.).
3. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Valdiation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
4. Boultwood J., Pellagati A., Nikpour M., Pushkaran B., Fidler C., Cattan H., et al. The role of iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008, 3:e1970.
5. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
6. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
7. Brunning R., Bennett J., Flandrin G., Matutes E., Head D., Vardiman J., et al. Refractory cytopenia with multilineage dysplasia. World Health Organization classification of tumours. Tumours of haematopoietic and lymphoid tissues 2001, 70. IARC Press, Lyon. 3rd ed. E. Jaffe, N. Harris, H. Stein, J. Vardiman (Eds.).
8. Löffler H., Raststetter J., Haferlach T. Atlas of clinical hematology 2004, Springer, Berlin. 6th ed.
9. Mufti G., Bennett J., Goasguen J., Bain B., Baumann I., Brunning R., et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2011, 93:1712-1717.
10. Schoch C., Schnittger S., Bursch S., Gerstner D., Hochhaus A., Berger U., et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002, 16:53-59.
11. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
12. Dicker F., Haferlach C., Kern W., Haferlach T., Schnittger S. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007, 110:1308-1316.
13. Bacher U., Haferlach T., Schoch C., Kern W., Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006, 107:3847-3853.
14. Schnittger S., Kinkelin U., Schoch C., Heinecke A., Haase D., Haferlach T., et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000, 14:796-804.
15. Schnittger S., Schoch C., Dugas M., Kern W., Staib P., Wuchter C., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
16. Haase D., Germing U., Schanz J., Pfeilstöcker M., Nösslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
17. Germing U., Strupp C., Kuendgen A., Isa S., Knipp S., Hildebrandt B., et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006, 91:1596-1604.
18. Navarro I., Ruiz M., Cabello A., Collado R., Ferrer R., Hueso J., et al. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. Leuk Res 2005, 30:971-977.
19. Breccia M., Carmosino I., Biondo F., Mancini M., Russo E., Latagliata R., et al. Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. Leuk Res 2005, 30:178-182.
20. Mohamedali A., Gaken J., Twine N.A., Ingram W., Westwood N., Lea N.C., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110:3365-3373.
21. Malcovati L., Papaemmanuil E., Bowen D., Boultwood J., Della-Porta M., Pascutto C., et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011, 118:6239-6246.
22. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
23. Kosmider O., Gelsi-Boyer V., Cheok M., Grabar S., La-Valle V., Picard F., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285-3291.